MDCK-MRP2 - Dkfz

212
Forschungsschwerpunkt C
Krebsrisikofaktoren und Krebsprävention
[8] Buchholz E., Drings P., Pilz L., Manegold C.: A single, center,
controlled study of standard versus dose intensified chemotherapy
with sequential reinfusion of hematopoetic progenitor
cells in small cell lung cancer, final results. Onkol. 26(S5), p.26
(V305), 2003.
[9] Buchholz E., Drings P., Pilz L., Manegold C.: Final results
from a single center, controlled study of standard versus dose
intensified chemotherapy with sequential reinfusion of
haematopoetic progenitor cells in small cell lung cancer.
Proc.ASCO , p.No.2572, 2003.
[10] Burkholder I., Kopp-Schneider A.: Incorporating phenotype-dependent
growth rates into the color-shift model for
preneoplastic hepatocellular lesions. Math.Biosci. 179 (2) 145-
160, 2002.
[11] Cochlovius B., Stassar M.J.J.G., Schreurs M.W., Benner
A., Adema G.J.: Oral DNA vaccination: antigen uptake and presentation
by dendritic cells elicits protective immunity.
Immunol.Lett. 80 (2) 89-96, 2002.
[12] Cremer F.W., Bouko Y., Everaert T., Lipinski E., Samson D.,
Apperely J.F., Thielemans K., Van Camp B., Benner A.,
Goldschmidt H., Moos M., Bakkus M.H.C.: Quantitation of the
post-transplantation tumor load in the bone marrow by PCR with
allele-specific oligonucleotide primers is a prognostic parameter in
multiple myeloma. Onkol. 25(S4), p.120 (419), 2002.
[13] Dally H., Edler L., Jäger B., Schmezer P., Spiegelhalder B.,
Dienemann H., Drings P., Schulz V., Kayser K., Bartsch H., Risch
A.: The CYP3A4*1B allele increases risk for small cell lung cancer:
effect of gender and smoking dose. Pharmacogen. 13 (10) 607-
618, 2003.
[14] Dally H., Gassner K., Jäger B., Schmezer P., Spiegelhalder
B., Edler L., Drings P., Dienemann H., Schulz V., Kayser K.,
Bartsch H., Risch A.: Myeloperoxidase (MPO) genotype and lung
cancer histologic types: the MPO-463 A allele is associated with
reduced risk for small cell lung cancer in smokers. Int.J.Cancer
102 (5) 530-535, 2002.
[15] Deichmann M., Thome M., Benner A., Egner U., Hartschuh
W., Näher H.: PTEN/MMAC1 expression in melanoma resection
specimens. Brit.J.Cancer 87 (12) 1431-1436, 2002.
[16] Dencausse Y., Hartung G., Sturm J., Kopp-Schneider A.,
Hagmüller E., Wojatschek C., Lindemann H., Fritze D., Queisser
W.: Adjuvant chemotherapy in stage III colon cancer with 5-fluorouracil
and levamisole versus 5-fluorouracil and leucovorin.
Onkol. 25 (5) 426-430, 2002.
[17] Dittrich C., Arndt D., Beck J., Behringer D., Berdel W.,
Bokemeyer C., Borner M., DeSantis M., Edler L., Eisenbrand G.,
Fichtner I., Fiebig H.H., Fricker G., Gastl G., Hartung G., Hofheinz
R., Hossfeld D.K., Illiger H.J., Jaehde U., Keppler B.K., Morant
R., Mross K.B., Müller H.J., Oberhoff C., Queisser W., Reichert
D., Reszka R., Scheulen M.E., Schüller J., Strumberg D., Pawel
J.v., Wiessler M.: CESAR-EWIV: A platform for developing new
anticancer agents. J.Cancer Res.Clin.Oncol. 128(Suppl.1), p.39
(I199), 2002.
[18] Döhner K., Tobis K., Ulrich R., Fröhling S., Benner A.,
Schlenk R.F., Döhner H.: Prognostic significance of partial tandem
duplications of the MLL gene in adult patients 16 to 60 years old
with acute myeloid leukemia and normal cytogenetics: a study of
the AML group Ulm. J.Clin.Oncol. 20 (15) 3254-3261, 2002.
[19] Dreger P., Stilgenbauer S., Benner A., Ritgen M., Kröber
A., Kneba M., Schmitz N., Döhner H.: The prognostic impact of
autologous stem cell transplantation in patients with chronic lymphocytic
leukemia: a risk-matched analysis based on on the VH
gene mutational status. Onkol. 26(S5), p.8 (V182), 2003.
[20] Edler L.: Anforderungen an die klinische Therapieforschung
in der Phase I, II und III. Onkol. 25 (Suppl.1) 78-83,
2002.
[21] Edler L.: Biometrische Bewertung palliativer Massnahmen.
In: D.Fritze (Ed.), Palliative Krebsbehandlung. Beiträge zur
interdisziplinären Krebsbehandlung. Zuckschwerdt, München,
2002, pp.7-25.
C060
Biostatistik
DKFZ 2004: Wissenschaftlicher Ergebnisbericht 2002 - 2003
[22] Edler L.: Comparing classification methods for protein fold
prediction: Support vector machines, neural networks and statistical
methods. p.39, 2002. Freiburg, Germany, Int.Biometr.Soc.
Proceedings XXIth International Biometric Conference, July 21-
26.
[23] Edler L.: Do new studies of iscador proof efficacy in cancer
patients? J.Cancer Res.Clin.Oncol. 128(Suppl.1), p.154
(P771), 2002.
[24] Edler L.: Statistical methods for toxicity detection and
testing. In: L.Chyczewski, et al. (Eds.), Endocrine disrupters and
carcinogenic risk assessment. IOS Press, Amsterdam, 2002,
pp.290-306.
[25] Edler L.: Chemotherapie mit komplementärer
Misteltherapie. Wie evident ist ihre Wirksamkeit wirklich?
Internist.Prax. 43 895-904, 2003.
[26] Edler L.: Mistel in der Krebstherapie. Dtsch.Ärztebl. 101
(1-2) A44-A49, 2004.
[27] Edler L., Geisler I., Rittgen W.: Meeting report. Symposium
on mathematical, statistical and computational methods for
cancer surveillance and cancer screening. July 27, 2001 Heidelberg,
Deutsches Krebsforschungszentrum. J.Cancer
Res.Clin.Oncol. 128 231-234, 2002.
[28] Edler L., Heinzl H.: Exploring the relationships between
exposure to PCDDS/FS and neurological health effects in humans.
Organohalogen Comp. 57 415-418, 2002.
[29] Edler L., Heinzl H.: Toxicokinetic modeling for environmental
health problems. Environmetrics 14 193-202, 2003.
[30] Edler L., Ittrich C.: Biostatistical methods for the validation
of alternative methods for the in vitro toxicity testing. ATLA
31 (Suppl.1) 5-41, 2003.
[31] Edler L., Kopp-Schneider A.: Phase III clinical trial:
myths around elementary statistical principles. Contr.Clin.Trials
24(3, Suppl.1), p.128S, 2003.
[32] Edler L., Kopp-Schneider A.: Randomized clinical trial:
Myths around elementary statisitcal principles. Onkol. 26 (6) 551-
556, 2003.
[33] Edler L., Pilz L.: Klinische Studien. In: C.Manegold (Ed.),
Therapieoptionen beim nicht-kleinzelligen Bronchialkarzinom. UNI-
MED, Bremen, 2002, pp.153-163.
[34] Edler L., Poirier K., Dourson M., Kleiner J., Mileson B.,
Nordmann H., Renwick A., Slob W., Walton K., Würtzen G.: Mathematical
modelling and quantitative methods. Food Chem.Toxicol.
40 (2/3) 283-326, 2002.
[35] Fischer L., Cardenas C., Thorn M., Benner A., Grenacher
L., Vetter M., Lehnert T., Klar E., Meinzer H.P., Lamade W.: Limits
of Couinaud’s liver segment classification: a quantitative computer-based
three-dimensional analysis.
J.Comput.Assist.Tomogr. 26 (6) 962-967, 2002.
[36] Fogel M., Gutwein P., Mechtersheimer S., Riedle S., Stöck
A., Smirnov A., Edler L., Ben-Arie A., Huszar M., Altevogt P.: L1
expression as a predictor of progression and survival in patients
with uterine and ovarian carcinomas. Lancet 362 869-875, 2003.
[37] Freier K., Joos S., Flechtenmacher C., Devens F., Benner
A., Bosch F.X., Lichter P., Hofele C.: Tissue microarray analysis
reveals site-specific prevalence of oncogene amplifications in
head and neck squamous cell carcinoma. Cancer Res. 63 (6)
1179-1182, 2003.
[38] Fröhling S., Schlenk R., Stolze I., Bihlmayr J., Kreitmeier S.,
Tobis K., Benner A., Döhner H.: CEBPA mutations in younger
adults with acute myeloid leukemia and normal cytogenetics:
prognostic relevance and analysis of cooperating mutations.
Onkol. 26(S5), p.18 (V224), 2003.
[39] Fröhling S., Schlenk R.F., Breitruck J., Benner A.,
Kreitmeier S., Tobis K., Döhner H., Döhner K.: Prognostic significance
of activating FLT3 mutations in younger adults (16 to 60
years) with acute myeloid leukemia and normal cytogenetics: a
study of the AML study group Ulm. Blood 100 (13) 4372-4380,
2002.